Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ASXC

ASXC - Asensus Surgical, Inc. Stock Price, Fair Value and News

0.29USD+0.01 (+3.57%)Delayed as of 23 Feb 2024, 10:55 am ET
Watchlist

Market Summary

USD0.29+0.01
Delayedas of 23 Feb 2024, 10:55 am
3.57%

ASXC Stock Price

View Fullscreen

ASXC RSI Chart

ASXC Valuation

Market Cap

74.0M

Price/Earnings (Trailing)

-0.94

Price/Sales (Trailing)

13.19

EV/EBITDA

-0.69

Price/Free Cashflow

-1.14

ASXC Price/Sales (Trailing)

ASXC Profitability

Operating Margin

-41.68%

EBT Margin

-1405.67%

Return on Equity

-167.37%

Return on Assets

-111.82%

Free Cashflow Yield

-88.06%

ASXC Fundamentals

ASXC Revenue

Revenue (TTM)

5.6M

Rev. Growth (Yr)

-57.51%

Rev. Growth (Qtr)

0.74%

ASXC Earnings

Earnings (TTM)

-79.1M

Earnings Growth (Yr)

3.2%

Earnings Growth (Qtr)

11.34%

Breaking Down ASXC Revenue

52 Week Range

0.250.86
(Low)(High)

Last 30 days

-9.1%

Last 90 days

25%

Trailing 12 Months

-59.9%

How does ASXC drawdown profile look like?

ASXC Financial Health

Current Ratio

3.79

ASXC Investor Care

Shares Dilution (1Y)

11.60%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20237.0M7.1M5.6M0
20227.2M7.1M7.1M7.1M
20214.7M5.1M6.9M8.2M
20207.0M4.0M2.8M3.2M
201921.5M18.8M15.4M8.5M
20189.9M14.7M20.0M24.1M
20173.3M5.0M3.8M7.1M
20160001.5M
20150000
20141.2M787.0K486.0K401.0K
20132.0M1.8M1.6M1.4M
20120002.1M
20110000
20100000

Tracking the Latest Insider Buys and Sells of Asensus Surgical, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 04, 2024
shameze rampertab
sold (taxes)
-40,599
0.27
-150,367
evp, chief financial officer
Feb 04, 2024
shameze rampertab
acquired
-
-
280,909
evp, chief financial officer
Feb 04, 2024
fernando anthony c. j.
sold (taxes)
-130,834
0.27
-484,572
president and ceo
Feb 04, 2024
fernando anthony c. j.
acquired
-
-
1,042,770
president and ceo
Dec 14, 2023
starling william n jr
bought
5,077
0.28
18,134
-
Dec 14, 2023
starling william n jr
sold
-5,077
0.28
-18,134
-
Jul 01, 2023
shameze rampertab
sold (taxes)
-3,557
0.51
-6,975
evp, chief financial officer
Jul 01, 2023
shameze rampertab
acquired
-
-
16,666
evp, chief financial officer
Jun 06, 2023
kwo elizabeth
acquired
-
-
45,000
-
Jun 06, 2023
pfenniger richard c jr
acquired
-
-
45,000
-

1–10 of 47

Which funds bought or sold ASXC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Able Wealth Management LLC
new
-
2,073
2,073
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
9,000
60,000
-%
Feb 16, 2024
STUDIO INVESTMENT MANAGEMENT LLC
unchanged
-
3.00
16.00
-%
Feb 16, 2024
O'Dell Group, LLC
new
-
25.00
25.00
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-61,000
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
15,192
15,192
-%
Feb 15, 2024
GTS SECURITIES LLC
reduced
-17.98
-320
10,017
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
272
29,424
38,073
-%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
sold off
-100
-3,348
-
-%
Feb 14, 2024
Creative Planning
added
0.88
2,265
14,094
-%

1–10 of 42

Are Funds Buying or Selling ASXC?

Are funds buying ASXC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ASXC
No. of Funds

Unveiling Asensus Surgical, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 20, 2023
state street corp
0.35%
817,129
SC 13G/A
Jul 08, 2022
blackrock inc.
1.6%
3,684,318
SC 13G
Feb 10, 2022
state street corp
5.42%
12,703,273
SC 13G
Feb 04, 2022
blackrock inc.
6.7%
15,793,991
SC 13G

Recent SEC filings of Asensus Surgical, Inc.

View All Filings
Date Filed Form Type Document
Feb 06, 2024
4
Insider Trading
Feb 06, 2024
4
Insider Trading
Jan 08, 2024
8-K
Current Report
Jan 04, 2024
8-K
Current Report
Dec 18, 2023
4
Insider Trading
Nov 16, 2023
8-K
Current Report

Peers (Alternatives to Asensus Surgical, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.1B
40.1B
0.08% 5.41%
36.19
5.16
-8.12% -17.45%
70.3B
19.5B
1.90% -2.48%
56
3.61
4.02% -22.04%
24.2B
3.8B
13.67% -2.23%
66.83
6.37
-1.48% -28.97%
21.3B
14.9B
3.05% 1.38%
8.03
1.43
2.01% 209.17%
MID-CAP
10.0B
12.7B
2.56% -12.12%
22.51
0.79
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.59
3.72
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.84
2.68
4.97% 18.89%
7.1B
3.9B
-8.15% -6.44%
-32.48
1.81
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-287.71
10.08
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.14
0.4
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.41
0.33
7.95% -543.98%
363.5M
163.3M
8.18% -20.52%
-14.79
2.23
7.14% -56.09%
238.7M
329.5M
3.17% -52.24%
-16.91
0.72
0.49% 64.22%
74.1M
50.3M
4.50% -30.54%
-4.89
1.47
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.37
1.19
5.77% 8.23%

Asensus Surgical, Inc. News

Latest updates
InvestorsObserver08 Feb 202408:00 am
Yahoo Finance08 Jan 202408:00 am
Securities.io3 months ago
Mass Device7 months ago

Asensus Surgical, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue0.7%1,089,0001,081,000976,0002,464,0002,563,000994,0001,066,0002,476,0002,571,0001,102,0002,083,0001,106,500814,000655,000600,000687,0002,024,0003,639,0002,181,0007,524,0005,422,000
Gross Profit10.7%-1,780,000-1,993,000-1,971,000166,000-1,841,000-1,353,000-757,000189,000-779,000-1,245,000-1,029,000514,000-609,000-758,000-1,138,000-10,195,000-1,422,000-297,000-286,0001,889,0001,173,000
Costs and Expenses---------------16,014,0002,110,00096,427,00022,197,00021,640,00020,114,00013,054,000
Operating Expenses-2.1%18,479,00018,870,00020,377,00018,293,00017,191,00018,214,00018,196,00015,873,00016,659,00014,839,00014,384,00014,222,50014,553,00013,608,00016,014,0002,109,00096,427,00022,197,000---
  S&GA Expenses-7.0%4,138,0004,449,0004,553,0003,820,0003,615,0003,602,0003,719,0003,229,0003,551,0003,562,0003,053,0002,773,5003,136,0002,901,0004,253,0005,589,0006,883,0007,868,0007,674,0007,901,0005,819,000
  R&D Expenses3.5%9,290,0008,980,00010,139,0008,520,0006,741,0007,253,0006,428,0006,575,0004,469,0004,089,0004,215,0003,755,5004,673,0004,257,0003,934,0004,634,0005,884,0006,295,0005,655,0006,439,0004,838,000
EBITDA Margin-25.4%-13.47-10.74-10.69-10.08-9.78-9.37-8.37-7.17-8.32-11.01-12.40-18.24---------
Interest Expenses-----30,00099,000141,000200,000293,00065,0005,0007,00019,000---200,0001,230,0001,061,0001,116,000810,500685,000
Income Taxes575.0%57,000-12,00091,00096,00055,00085,00080,000230,00032,0002,000-40,000-130,0002,000-691,000-697,000-575,000-1,070,000-869,000-610,000-823,000-781,000
Earnings Before Taxes11.7%-18,261,000-20,674,000-22,127,000-17,796,000-18,869,000-19,534,000-19,044,000-15,652,000-16,037,000-13,170,000-17,378,000-13,921,500-15,080,000-14,531,000-17,295,000-14,308,000-98,841,000-21,040,000-23,135,000-7,264,000-20,987,000
EBT Margin-25.3%-14.06-11.22-11.19-10.62-10.30-9.89-8.86-7.56-8.82-11.66-13.08-19.16---------
Net Income11.3%-18,318,000-20,662,000-22,218,000-17,890,000-18,924,000-19,619,000-19,128,000-15,881,000-16,069,000-13,172,000-17,340,000-13,791,500-15,082,000-13,840,000-16,598,000-13,733,000-97,771,000-20,171,000-22,525,000-6,441,000-20,206,000
Net Income Margin-25.3%-14.10-11.25-11.24-10.66-10.36-9.95-8.91-7.59-8.80-11.63-12.89-18.68---------
Free Cashflow14.9%-15,371,000-18,058,000-17,312,000-14,428,000-15,115,000-14,484,000-16,189,000-13,702,000-9,140,000-8,553,000-10,632,000-12,765,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-9.8%71.0078.0097.0011612914716718620021222478.0080.0076.0084.0075.0098.00203217239228
  Current Assets-16.4%46.0055.0072.0087.0010410911911313517418234.0038.0034.0040.0028.0047.0069.0082.00102106
    Cash Equivalents182.3%22.008.0019.006.0015.0012.0026.0019.0061.0015816618.0021.0016.0023.0011.0023.0024.0026.0022.0042.00
  Inventory-26.4%7.009.009.008.009.008.009.009.0012.0013.0011.0010.0011.0011.0010.0011.0014.0020.0015.0011.0010.00
  Net PPE4.8%9.009.009.0010.009.009.0010.0011.0010.0010.009.0010.009.007.006.005.005.006.006.006.007.00
  Goodwill------------------80.0080.0080.0071.00
Liabilities39.2%23.0017.0017.0016.0016.0016.0016.0017.0018.0016.0018.0017.0018.0016.0017.0019.0034.0072.0070.0071.0063.00
  Current Liabilities13.9%12.0011.0011.0010.0010.0010.009.0010.009.008.0010.0010.0012.0010.0013.0013.0012.0023.0020.0022.0012.00
  Long Term Debt-----------0.002.003.003.00-------
    LT Debt, Current-----------2.001.000.00--------
    LT Debt, Non Current-----------0.002.003.00--------
Shareholder's Equity-23.2%47.0062.0080.0010011313115116918219620662.0062.0060.0067.0056.0064.00131147169164
  Retained Earnings-2.0%-922-903-883-860-843-824-804-785-769-753-740-722-709-694-680-663-649-552-531-509-502
  Additional Paid-In Capital0.5%971966964963961959957955950947945781770755750720716683679677664
Shares Outstanding10.1%264240239237236237236235234234205116---------
Float------93.00---732---29.00---245---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations16.2%-15,049-17,956-17,248-14,053-14,654-14,287-15,943-13,172-9,002-8,248-10,237-12,765-8,774-12,659-12,477-14,368-19,578-15,343-24,195-12,852-16,451
  Share Based Compensation2.1%2,0191,9781,9162,0552,0332,0832,2452,8402,9611,8421,7862,1111,9441,9331,9231,7813,3913,3552,9812,3452,490
Cashflow From Investing216.5%20,7786,56429,7376,32718,03712823,045-30,598-88,370-305-395---1.00-2.0015,9209,79712,94028,988-17,900-39,751
Cashflow From Financing4922.2%9,743194-483--1.005.00-3361,56433.00503159,6058,93613,6496,08124,704-14,3448,730268-26310,311156

ASXC Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Revenue$ 1,089,000$ 2,563,000$ 3,146,000$ 4,623,000
Cost of revenue:    
Cost of revenue2,869,0004,404,0008,890,0008,574,000
Gross loss(1,780,000)(1,841,000)(5,744,000)(3,951,000)
Operating expenses:    
Research and development9,290,0006,741,00028,409,00020,422,000
Sales and marketing4,138,0003,615,00013,140,00010,936,000
General and administrative4,571,0004,853,00015,163,00015,378,000
Amortization of intangible assets114,0002,398,000340,0007,601,000
Change in fair value of contingent consideration366,000(416,000)674,000(1,168,000)
Impairment of property and equipment000432,000
Total operating expenses18,479,00017,191,00057,726,00053,601,000
Operating loss(20,259,000)(19,032,000)(63,470,000)(57,552,000)
Other income (expense), net    
Change in fair value of warrant liabilities2,278,00002,278,0000
Interest income406,000291,0001,276,000806,000
Interest expense0(99,000)0(440,000)
Other expense, net(686,000)(29,000)(1,146,000)(261,000)
Total other income, net1,998,000163,0002,408,000105,000
Loss before income taxes(18,261,000)(18,869,000)(61,062,000)(57,447,000)
Income tax expense57,00055,000136,000224,000
Net loss$ (18,318,000)$ (18,924,000)$ (61,198,000)$ (57,671,000)
Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share)$ (0.07)$ (0.08)$ (0.25)$ (0.24)
Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares)256,184236,713244,744236,373
Comprehensive loss:    
Net loss$ (18,318,000)$ (18,924,000)$ (61,198,000)$ (57,671,000)
Foreign currency translation (loss) gain(640,000)(1,655,000)84,000(4,018,000)
Unrealized gain (loss) on available-for-sale investments67,00086,000473,000(610,000)
Comprehensive loss(18,891,000)(20,493,000)(60,641,000)(62,299,000)
Product [Member]    
Revenue:    
Revenue301,0001,964,000892,0002,565,000
Cost of revenue:    
Cost of revenue1,171,0003,057,0004,008,0004,316,000
Service [Member]    
Revenue:    
Revenue295,000335,000779,0001,067,000
Cost of revenue:    
Cost of revenue581,000365,0001,849,0001,506,000
Lease [Member]    
Revenue:    
Revenue493,000264,0001,475,000991,000
Cost of revenue:    
Cost of revenue$ 1,117,000$ 982,000$ 3,033,000$ 2,752,000

ASXC Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 21,669$ 6,329
Short-term investments, available-for-sale11,42064,195
Accounts receivable, net6622,256
Inventory, net6,6838,284
Prepaid expenses4,1743,584
Employee retention tax credit receivable0554
Other current assets1,3241,671
Total Current Assets45,93286,873
Restricted cash1,6151,141
Long-term investments, available-for-sale03,865
Inventory, net of current portion5,6405,469
Property and equipment, net9,2379,542
Intellectual property, net1,2781,576
Deferred tax assets, net150174
Operating lease right-of-use assets, net5,0044,950
Other noncurrent assets1,8712,463
Total Assets70,727116,053
Current Liabilities:  
Accounts payable4,5263,348
Accrued employee compensation and benefits4,9674,508
Accrued expenses and other current liabilities1,2581,293
Operating lease liabilities, current916800
Deferred revenue456465
Total Current Liabilities12,12310,414
Long-Term Liabilities:  
Warrant liabilities4,8420
Contingent consideration1,9301,256
Operating lease liabilities, noncurrent4,5794,738
Total Liabilities23,47416,408
Stockholders' Equity:  
Common stock $0.001 par value, 750,000,000 shares authorized at September 30, 2023 and December 31, 2022; 264,111,257 and 236,895,440 issued and outstanding at September 30, 2023 and December 31, 2022, respectively264237
Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at September 30, 2023 and December 31, 202200
Additional paid-in capital970,952962,731
Accumulated deficit(922,133)(860,935)
Accumulated other comprehensive loss(1,830)(2,388)
Total Stockholders' Equity47,25399,645
Total Liabilities and Stockholders' Equity70,727116,053
Intellectual Property [Member]  
Current Assets:  
Intellectual property, net$ 1,278$ 1,576
ASXC
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
 CEO
 WEBSITEwww.asensus.com
 EMPLOYEES183

Asensus Surgical, Inc. Frequently Asked Questions


What is the ticker symbol for Asensus Surgical, Inc.? What does ASXC stand for in stocks?

ASXC is the stock ticker symbol of Asensus Surgical, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Asensus Surgical, Inc. (ASXC)?

As of Thu Feb 22 2024, market cap of Asensus Surgical, Inc. is 74.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASXC stock?

You can check ASXC's fair value in chart for subscribers.

What is the fair value of ASXC stock?

You can check ASXC's fair value in chart for subscribers. The fair value of Asensus Surgical, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Asensus Surgical, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASXC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Asensus Surgical, Inc. a good stock to buy?

The fair value guage provides a quick view whether ASXC is over valued or under valued. Whether Asensus Surgical, Inc. is cheap or expensive depends on the assumptions which impact Asensus Surgical, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASXC.

What is Asensus Surgical, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ASXC's PE ratio (Price to Earnings) is -0.94 and Price to Sales (PS) ratio is 13.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASXC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Asensus Surgical, Inc.'s stock?

In the past 10 years, Asensus Surgical, Inc. has provided -0.346 (multiply by 100 for percentage) rate of return.